We are live on ! Find out more
OA

Oak Associates Portfolio holdings

AUM $1.49B
1-Year Est. Return 34.25%
This Fund
S&P 500
This Quarter Est. Return
-17.24%
1 Year Est. Return
+34.25%
3 Year Est. Return
+111.6%
5 Year Est. Return
+123.41%
10 Year Est. Return
+571.62%
AUM
$1.28B
AUM Growth
-$359M
Cap. Flow
-$60.5M
Cap. Flow %
-4.73%
Top 10 Hldgs %
43.57%
Holding
141
New
3
Increased
11
Reduced
53
Closed
12

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$1.34M
2
BIO icon
Bio-Rad Laboratories Class A
BIO
+$1.33M
3
PFE icon
Pfizer
PFE
+$762K
4
PYPL icon
PayPal
PYPL
+$467K
5
MEDP icon
Medpace
MEDP
+$463K

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$7.62M
2
DKNG icon
DraftKings
DKNG
+$5.16M
3
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$4.7M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$3.88M
5
EBAY icon
eBay
EBAY
+$3.76M

Sector Composition

Rank Sector Weight
1 Technology 41.48%
2 Healthcare 16.66%
3 Communication Services 14.06%
4 Consumer Discretionary 12.31%
5 Financials 11.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
26
Pfizer
PFE
$140B
$16.9M 1.32%
322,997
+14,946
+5% +$762K
VMW
27
DELISTED
VMware, Inc
VMW
$16.8M 1.31%
147,172
-24,988
-15% -$2.84M
LH icon
28
Labcorp
LH
$24.3B
$16.2M 1.27%
80,698
-30
-0% -$6.39K
ALC icon
29
Alcon
ALC
$33.1B
$15.3M 1.2%
218,900
-28,408
-11% -$2.07M
MCK icon
30
McKesson
MCK
$98.5B
$14.8M 1.16%
45,515
-6,788
-13% -$2.17M
AKAM icon
31
Akamai
AKAM
$16.8B
$13.7M 1.07%
149,740
– –
ZBH icon
32
Zimmer Biomet
ZBH
$17.7B
$13M 1.02%
124,056
-615
-0.5% -$73K
CRM icon
33
Salesforce
CRM
$134B
$11.9M 0.93%
72,300
-11,731
-14% -$2.07M
NTAP icon
34
NetApp
NTAP
$32.9B
$11.5M 0.9%
176,765
-20
-0% -$1.44K
ACN icon
35
Accenture
ACN
$89.9B
$11.4M 0.89%
40,902
-7,000
-15% -$2.1M
GPN icon
36
Global Payments
GPN
$22.1B
$11.3M 0.88%
101,704
+12
+0% +$1.52K
DOX icon
37
Amdocs
DOX
$5.53B
$9.11M 0.71%
109,403
– –
GNTX icon
38
Gentex
GNTX
$4.88B
$8.04M 0.63%
287,392
– –
AIZ icon
39
Assurant
AIZ
$13.7B
$7.41M 0.58%
42,876
+8
+0% +$1.45K
GILD icon
40
Gilead Sciences
GILD
$161B
$7.36M 0.58%
119,057
-1,609
-1% -$99.6K
CHKP icon
41
Check Point Software Technologies
CHKP
$13.3B
$7.2M 0.56%
59,143
-6,000
-9% -$770K
GSK icon
42
GSK
GSK
$103B
$6.76M 0.53%
124,284
-16
-0% -$883
STT icon
43
State Street
STT
$50.9B
$6.71M 0.52%
108,817
-1,343
-1% -$95K
MDT icon
44
Medtronic
MDT
$107B
$6.61M 0.52%
73,626
– –
ILMN icon
45
Illumina
ILMN
$29.4B
$6.45M 0.5%
35,980
+1,384
+4% +$353K
ISRG icon
46
Intuitive Surgical
ISRG
$121B
$6.08M 0.48%
30,292
– –
PAYX icon
47
Paychex
PAYX
$40.4B
$5.92M 0.46%
52,019
-5
-0% -$628
MHO icon
48
M/I Homes
MHO
$3.83B
$4.94M 0.39%
124,540
-3,497
-3% -$152K
BNY
49
Bank of New York Mellon
BNY
$108B
$4.78M 0.37%
114,533
+28
+0% +$1.25K
DGX icon
50
Quest Diagnostics
DGX
$25.1B
$4.19M 0.33%
31,480
– –
1
2
3 4 5

Similar funds

FAT
First American Trust Santa Ana, California $1.49B AUM 21.98% 1-Year Est. Return
AIA
Ally Invest Advisors Charlotte, North Carolina $1.49B AUM 14.08% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.49B AUM 10.4% 1-Year Est. Return
PIM
Plato Investment Management Sydney, NSW, Australia $1.49B AUM 28.65% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RIM
Rush Island Management New York $1.49B AUM 4.65% 1-Year Est. Return
SB
Simmons Bank Pine Bluff, Arkansas $1.49B AUM 23.32% 1-Year Est. Return
MHS
M Holdings Securities Portland, Oregon $1.48B AUM 26.15% 1-Year Est. Return

Oak Associates's Q2 2022 Portfolio in Review

As of Q2 2022, Oak Associates held 141 positions worth $1.28B, down 22% from $1.64B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Oak Associates withdrew a net $60.5M in Q2 2022, closing 12 positions and reducing 53 holdings. Its most notable exit was DraftKings, an estimated $5.16M position sold in full.

By sector, the portfolio is most concentrated in Technology at 41% of assets, down from 42% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, Oak Associates opened a new position in Moderna worth $1.34M.

  • Oak Associates's largest Q2 2022 buy was Moderna: 9,393 shares worth $1.34M.
  • Oak Associates added most to Pfizer in Q2 2022, an estimated $762K increase.
  • Oak Associates's biggest Q2 2022 reduction was Apple, cutting an estimated $7.62M.
  • Oak Associates fully exited DraftKings in Q2 2022, selling an estimated $5.16M.
  • Oak Associates's ten largest holdings make up 44% of its $1.28B portfolio in Q2 2022.
  • Oak Associates opened 3 new positions and closed 12 in Q2 2022.
  • Oak Associates's portfolio value fell 22% quarter-over-quarter to $1.28B.

Based on Oak Associates's 13F filing for Q2 2022, filed 12 Aug 2022.